Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Wasilijiang, Wahafu"'
Autor:
Fei Liu, Zixian Wang, Xiaofan Li, Zhen Zhang, Yue Yang, Junquan Chen, Dinghua Chen, Lingling Wu, Xiangyu Liu, Sujun Han, Fangming Wang, Wasilijiang Wahafu, Yibo Gao, Shancheng Ren, Nianzeng Xing, Guangyan Cai, Xiangmei Chen
Publikováno v:
Cancer Communications, Vol 43, Iss 2, Pp 214-224 (2023)
Abstract With the development and introduction of immune checkpoint inhibitors (ICIs) in cancer patients, immune‐related side effects have increasingly attracted attention. However, the risks of immune‐related renal toxicity are poorly characteri
Externí odkaz:
https://doaj.org/article/9d04ad5b092a44c9acac44901ff6347a
Autor:
Hongzhuang Wen, Yong Zhang, Zhan Yang, Zhao Zhai, Zhenwei Han, Hu Wang, Mingshuai Wang, Hongzhe Shi, Xi Chen, Wasilijiang Wahafu, Kaopeng Guan, Xiaolu Wang
Publikováno v:
Videosurgery and Other Miniinvasive Techniques, Vol 18, Iss 2, Pp 313-327 (2022)
Externí odkaz:
https://doaj.org/article/95dd3ec72f694e93b23d1ef6433e1bf9
Autor:
Wei, Houyi, Wang, Mingshuai, Wasilijiang, Wahafu, Zhou, Xiaoguang, Cui, Liyan, Song, Liming, Xing, Nianzeng, Niu, Yinong
Publikováno v:
In Asian Journal of Surgery April 2022 45(4):987-992
Autor:
Adili Keranmu, Mingshuai Wang, Yajian Li, Feiya Yang, Wasilijiang Wahafu, Dong Chen, Jing Liang, Kaopeng Guan, Nianzeng Xing
Publikováno v:
BMC Urology, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background To explore the feasibility of single-position laparoscopic radical nephrectomy (LRN) and tumor thrombectomy for left renal cell carcinoma with high-risk Mayo 0 and 1 tumor thrombus (TT). Methods All patients with left renal cell c
Externí odkaz:
https://doaj.org/article/451e3f0b9cdb4da1be588720d5755e10
Autor:
Georgi Tosev, Wasilijiang Wahafu, Philipp Reimold, Ivan Damgov, Constantin Schwab, Cem Aksoy, Adam Kaczorowski, Albrecht Stenzinger, Joanne Nyarangi-Dix, Markus Hohenfellner, Stefan Duensing
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
Abstract There are currently five programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors approved for the treatment of locally advanced or metastatic urothelial carcinoma (UC) of the bladder. For platinum-ineligible patients, testing
Externí odkaz:
https://doaj.org/article/e0963328ed3e40d1b1cbaada103b02e7
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
It is well known that the role of gut microbiota in drug metabolism, especially in oral difficult absorbable drugs. Understanding the gut microbiota could enable us to understand drugs in new ways. The purpose of the study was to investigate explore
Externí odkaz:
https://doaj.org/article/4966cc0683ee4016ad2451ea9b8e3fde
Autor:
Wasilijiang Wahafu, Sai Liu, Wenbin Xu, Mengtong Wang, Qingbao He, Liming Song, Mingshuai Wang, Feiya Yang, Lin Hua, Yinong Niu, Nianzeng Xing
Publikováno v:
BMC Urology, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Bladder cancer is a complex disease associated with high morbidity and mortality. Management of bladder cancer before radical cystectomy continues to be controversial. We compared the long-term efficacy of one-shot neoadjuvant int
Externí odkaz:
https://doaj.org/article/e64d97f428134e1a9ff3c9c667bc0e75
Autor:
Georgi Tosev, Wasilijiang Wahafu, Philipp Reimold, Ivan Damgov, Constantin Schwab, Cem Aksoy, Adam Kaczorowski, Albrecht Stenzinger, Joanne Nyarangi‑Dix, Markus Hohenfellner, Stefan Duensing
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/fac61807f2bf4e8a8ce9cde48b89bf41
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 120, Iss , Pp - (2019)
Background: Emerging preclinical evidence suggests a critical role for androgen-mediated androgen receptor (AR) signaling in bladder cancer progression. However, researchers have not determined whether autophagy modulates the efficacy of an enzalutam
Externí odkaz:
https://doaj.org/article/e7fcbd8e44034bb1a4627527f060823a
Autor:
Fei Liu, Zixian Wang, Xiaofan Li, Zhen Zhang, Yue Yang, Junquan Chen, Dinghua Chen, Lingling Wu, Xiangyu Liu, Sujun Han, Fangming Wang, Wasilijiang Wahafu, Yibo Gao, Shancheng Ren, Nianzeng Xing, Guangyan Cai, Xiangmei Chen
Publikováno v:
Cancer communications (London, England)REFERENCES.
With the development and introduction of immune checkpoint inhibitors (ICIs) in cancer patients, immune-related side effects have increasingly attracted attention. However, the risks of immune-related renal toxicity are poorly characterized. In this